Health ❯ Healthcare ❯ Drug Development

Clinical Research

Phase 3 Trials Efficacy Studies Patient Enrollment Povetacicept Peptide Inhibitors SpringWorks Therapeutics Genetic Studies Therapeutics Phase 3 Studies Patient Safety

Karyopharm Raises $30 Million in RA Capital Private Placement

The structure ties potential extra funding to Phase 3 selinexor results.

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Alveus Therapeutics Launches With $159.8 Million Series A to Advance Next‑Generation Obesity Drugs

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Novo Nordisk Halts Phase-3 Alzheimer’s Trial of Semaglutide After Failure to Slow Decline

Novartis’ Fabhalta Slows Kidney Function Decline in Final Phase 3 IgAN Results

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Phase 3 Trial in Nature Medicine Finds Cannabis-Derived Drug Eases Chronic Low Back Pain

STAT3 Decoy Shows Early Promise in First Cat Cancer Trial, Pointing Toward Human Studies

Korean Biotech Firms Mark Record Presence at BIO USA 2025

Study Reveals Sex-Based Protein Differences Driven by Non-Genetic Factors

Sanofi and J&J Halt E. coli Vaccine Trial After Insufficient Efficacy

Breakthrough Alzheimer's Drug Targets Key Tau Protein Hotspots